Know Cancer

or
forgot password

Neoadjuvant Chemotherapy in Resectable NSCLC Stages IB, IIA, IIB, and IIIA/T3 But Not IIIA/N2


Phase 3
18 Years
75 Years
Not Enrolling
Both
Non-small Cell Lung Cancer

Thank you

Trial Information

Neoadjuvant Chemotherapy in Resectable NSCLC Stages IB, IIA, IIB, and IIIA/T3 But Not IIIA/N2


Randomisation between 3 courses of neoadjuvant Carboplatin plus Paclitaxel or no
chemotherapy before surgery.


Inclusion Criteria:



- NSCLC

- Stages IB, IIA, IIB, IIIA/T3

- Lung function test allowing surgery

- Age 18-75 years

Exclusion Criteria:

- Poor lung function

- Performance status 3-4

- Mediastinal lymph node involvement

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Survival

Principal Investigator

Jens B. Sorensen, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Dept. Oncology, Rigshospitalet

Authority:

Denmark: National Board of Health

Study ID:

Neoadjuvant treatment in NSCLC

NCT ID:

NCT00273507

Start Date:

January 1998

Completion Date:

January 2006

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Non-small cell lung cancer
  • neoadjuvant
  • resection
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location